# PrEP My Way: A hybrid type 1 clinical effectiveness-implementation trial to promote PrEP persistence among young Kenyan women

> **NIH NIH R01** · MASSACHUSETTS GENERAL HOSPITAL · 2024 · $682,691

## Abstract

PROJECT SUMMARY. Significance: Young women account for 63% of all new HIV infections in sub-Saharan
Africa and are thus a high priority population for pre-exposure prophylaxis (PrEP). Because adherence and
persistence to PrEP as oral emtricitabine/tenofovir have generally been low, new interventions are needed to
facilitate PrEP use. Injectable cabotegravir (CAB-LA) and the dapivirine vaginal ring, as well as choice of
adherence support, are promising approaches to increase PrEP use; however, a key remaining need is a
mechanism to effectively engage with young women over time. Intervention: PrEP My Way is a novel PrEP
delivery system based on Social Cognitive Theory involving clinic-based PrEP initiation, followed by peer-
delivered kits for HIV self-testing, PrEP refills, vaginal swabs for sexually transmitted infection (STI) self-
sampling, pregnancy tests, and family planning, if desired. Pilot research demonstrated high feasibility and
acceptability of PrEP My Way as an effective means to engage young women in care. PrEP use was modest
overall although improved compared to clinic-based delivery. When combined with choice of PrEP formulation
and adherence support tools, PrEP My Way is well positioned to create an optimized means to promote PrEP
use for young women in sub-Saharan Africa. Innovation: PrEP My Way is the first, to our knowledge, peer-
delivered kit for holistic sexual health services that enables choice of PrEP formulation and adherence support,
combining key complementary evidence-based approaches for promoting PrEP use among young women.
Approach: In Aim 1, we will augment PrEP My Way to include CAB-LA and the dapivirine vaginal ring, as well
as choice of peer-based adherence support (SMS, routine check-ins, or WhatsApp groups). In Aim 2, we will
conduct a type 1 effectiveness-implementation trial of PrEP My Way vs enhanced standard of care in Kisumu,
Kenya in 432 young women over 1 year. We will assess the intervention with and without STI testing to assess
the marginal impact of the most costly kit component beyond PrEP. Our primary outcome will be prevention-
effective PrEP persistence (i.e., continued use by those with ongoing HIV prevention needs) by documented
injection (CAB-LA) or drug levels (ring, oral) at Month 9. Secondary outcomes will be prevention-effective
persistence and adherence at other time points, STI testing, and use of family planning. We will also track
implementation, service, and participant metrics using the Proctor framework. In Aim 3, we will conduct cost
and cost-effectiveness analyses of the intervention with and without STI testing. Investigators/environment:
Our team has the critical expertise needed for the success of this proposal: PrEP adherence/persistence and
implementation science (Dr. Haberer), PrEP/sexual health service delivery (Dr. Bukusi), PrEP formulation and
adherence support choice (Dr. Ngure), cost-effectiveness analysis (Dr. Barnabas), and intervention design
(ARK Africa, Dr. Sieg...

## Key facts

- **NIH application ID:** 11009178
- **Project number:** 1R01MH138255-01
- **Recipient organization:** MASSACHUSETTS GENERAL HOSPITAL
- **Principal Investigator:** Elizabeth Anne BUKUSI
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $682,691
- **Award type:** 1
- **Project period:** 2024-07-23 → 2029-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11009178

## Citation

> US National Institutes of Health, RePORTER application 11009178, PrEP My Way: A hybrid type 1 clinical effectiveness-implementation trial to promote PrEP persistence among young Kenyan women (1R01MH138255-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/11009178. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*